SHOW THE TRUTH. PICTURE WARNINGS SAVE LIVES

Read the rest of this entry »

BUFFALO, NY- A new cancer drug shows promising results in patients with metastatic cancer. The phase I clinical trial research will be presented by Alex A. Adjei, MD, PhD, Senior Vice President for Clinical Research and the Katherine Anne Gioia Chair in Cancer Medicine at Roswell Park Cancer Institute (RPCI), at the American Society of Clinical Oncology (ASCO) 2009 annual meeting, May 29 – June 2, in Orlando, FL.

Read the rest of this entry »

BUFFALO, NY- Patients diagnosed with non-Hodgkin’s lymphoma who become resistant to standard therapies may have a new treatment option. Scientists in the Lymphoma Translational Research Laboratory at Roswell Park Cancer Institute analyzed the mechanisms to overcome treatment resistance, including a new drug combination. Francisco J. Hernandez-Ilizaliturri, MD, Departments of Medicine and Immunology, Roswell Park Cancer Institute (RPCI), will present the findings at the American Society of Clinical Oncology (ASCO) 2009 annual meeting, May 29 – June 2, in Orlando, FL.

Read the rest of this entry »

PITTSBURGH, May 30, 2009 – Patients undergoing treatment for advanced head and neck cancers may respond well to the addition of gefinitib to chemotherapy, according to a study sponsored by the Eastern Cooperative Oncology Group and chaired by Ethan Argiris, MD, associate professor of medicine, University of Pittsburgh School of Medicine, and co-leader of the Head and Neck Cancer Program of the University of Pittsburgh Cancer Institute (UPCI). The results will be disclosed at the 45th annual meeting of the American Society of Clinical Oncology (ASCO) on May 30 in Orlando, Fla.

Read the rest of this entry »

ORLANDO, May 31, 2009 – Patients with esophageal cancer who require surgery may benefit from having minimally invasive surgery instead of an open esophagectomy, or removal of the esophagus, according to a University of Pittsburgh Cancer Institute (UPCI) phase II study. The results will be presented May 31 at the 45th annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Fla.

Read the rest of this entry »

April 15, 2009

NEW YORK, NY - A novel, minimally invasive surgical approach to treat stomach cancer has been shown to have advantages that may make it a preferable treatment for some patients.

“Laparoscopic gastrectomy is an excellent option for certain patients with the disease, and for those patients, this approach has the same success rate as standard open surgery, with significantly fewer complications.”– Vivian E. Strong, MD, study's lead author

A new study led by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) compares traditional “open” surgery to remove the stomach with laparoscopic gastrectomy - a minimally invasive procedure in which the surgeon removes the stomach while guided by a magnified image projected by a thin, lighted tube with a video camera at its tip, called a laparoscope. The findings demonstrate that while laparoscopic surgeries generally took longer to perform than open procedures, the minimally invasive approach yielded shorter hospital stays, decreased need for postoperative pain relief, fewer complications after surgery, and similar rates of recurrence-free survival after 36 months of follow-up. Read the rest of this entry »

May 27, 2009

NEW YORK, NY - Charles Sawyers, MD, Director of the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center (MSKCC) and a Howard Hughes Medical Institute investigator, has been named a “Dream Team” leader by Stand Up To Cancer and will co-lead a collaborative team that will receive $15 million to study targeted therapies to treat women's cancers. Read the rest of this entry »

BUFFALO, NY- Roswell Park Cancer Institute (RPCI) scientists are investigating a promising drug for chronic myeloid leukemia (CML) patients who have become intolerant or resistant to standard therapies. Meir Wetzler, MD, Department of Medicine at Roswell Park Cancer Institute, analyzed the effectiveness of omacetaxine (OM) in an ongoing phase II clinical study and will present the findings at the American Society of Clinical Oncology (ASCO) 2009 annual meeting, May 29 – June 2, in Orlando, FL.

Read the rest of this entry »

For more information, or to register online BEFORE May 28 at 5 p.m., click here.

DETROIT – Metro Detroiters have shown time and again that even in the most challenging of times, their generosity and support for others is heartfelt and unwavering. At a period when most headlines across the nation and world paint a somewhat bleak picture of Detroit and its future, nowhere do we feel a more determined spirit to rise above these challenges than right here in the Motor City. Just ask any of the 30,000 plus participants and the more than 100 local sponsors and underwriters who will take part in the 2009 Susan G. Komen Detroit Race for the Cure®, on Saturday, May 30, at Comerica Park, in Detroit. Read the rest of this entry »

May 26, 2009 | A first-of-its-kind clinical trial exploring a way to diagnose cancer in its earliest stages is being conducted at the UAMS Winthrop P. Rockefeller Cancer Institute through a National Cancer Institute grant.

Read the rest of this entry »